Elsevier

Life Sciences

Volume 84, Issues 25–26, 19 June 2009, Pages 876-881
Life Sciences

Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice

https://doi.org/10.1016/j.lfs.2009.03.022Get rights and content

Abstract

Aim

Glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) are major incretins associated with body weight regulation. Dipeptidyl peptidase-IV (DPP-IV) inhibitor increases plasma active GLP-1 and GIP. However, the magnitude of the effects of enhanced GLP-1 and GIP signaling by long-term DPP-IV inhibition on body weight and insulin secretion has not been determined. In this study, we compared the effects of long-term DPP-IV inhibition on body composition and insulin secretion of high fat diet (HFD)-fed wild-type (WT) and GLP-1R knockout (GLP-1R−/−) mice.

Main methods

HFD-fed WT and GLP-1R−/− mice were treated with or without DPP-IV inhibitor by drinking water. Food and water intake and body weight were measured during 8 weeks of study. CT-based body composition analysis, Oral glucose tolerance test (OGTT), batch incubation study for insulin secretion and quantitative RT-PCR for expression of incretin receptors in isolated islets were performed at the end of study.

Key findings

DPP-IV inhibitor had no effect on food and water intake and body weight, but increased body fat mass in GLP-1R−/− mice. DPP-IV inhibitor-treated WT and GLP-1R−/− mice both showed increased insulin secretion in OGTT. In isolated islets of DPP-IV inhibitor-treated WT and GLP-1R−/− mice, glucose-induced insulin secretion was increased and insulin secretion in response to GLP-1 or GIP was preserved, without downregulation of incretin receptor expression.

Significance

Long-term DPP-IV inhibition may maintain body composition through counteracting effects of GLP-1 and GIP while improving glucose tolerance by increasing glucose-induced insulin secretion through the synergistic effects of GLP-1 and GIP.

Introduction

Oral glucose administration leads to much greater insulin release than the equivalent intravenous glucose challenge. Gut hormonal substances released in response to glucose include the incretins glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide /glucose-dependent insulinotropic peptide (GIP), which are responsible for ~ 50% of postprandial insulin release. GLP-1 and GIP potentiate glucose-induced insulin secretion from pancreatic β-cells by binding their respective receptors and subsequently increasing the intracellular cAMP concentration. In addition to their action on the enteroinsular axis, GLP-1 inhibits glucagon secretion (Komatsu et al. 1989), delays gastric emptying (Willms et al. 1996), decreases body weight through suppression of appetite (Turton et al. 1996), and suppresses β-cell apoptosis (Toyoda et al. 2008), while GIP enhances energy storage in adipocytes (Miyawaki et al. 2002) and calcium accumulation in bone (Tsukiyama et al. 2006). Thus, the incretins are associated with various systems of metabolic homeostasis, including that of both glucose and body weight.

However, the effects of GLP-1 and GIP are limited by their short half-life of a few minutes, which is primarily due to the action of dipeptidyl peptidase-IV (DPP-IV). DPP-IV is an enzyme distributed throughout the body including plasma and the endothelial lining of several organs, and cleaves two amino acids of biologically active peptides including GLP-1 and GIP by recognizing proline or alanine in the second N-terminal amino acid. The resulting N-terminal-truncated forms of GLP-1 and GIP are devoid of bioactivity. Since DPP-IV-deficient rodents show improved glucose tolerance and increased insulin secretion with elevated plasma active GLP-1 levels after oral glucose loading (Marguet et al., 2000, Nagakura et al., 2001), DPP-IV inhibitor and DPP-IV-resistant GLP-1 receptor agonist are potential targets for the treatment of type 2 diabetes mellitus as a new class of antidiabetic agent. GLP-1 receptor agonist both increases insulin secretion and improves glucose tolerance and decreases body weight in rodents and humans (Szayna et al., 2000, Buse et al., 2004). DPP-IV inhibitor also increases insulin secretion and improves glucose tolerance, but its effect on body weight is controversial (Pospisilik et al., 2002, Lamont and Drucker, 2008, Reimer et al., 2002, Ahrén et al., 2002). It is reported that DPP-IV inhibitor do not increase insulin secretion after glucose loading in GLP-1 receptor (GLP-1R)/GIP receptor (GIPR) double knockout (DIRKO) mice, indicating that both GLP-1 and GIP are critically involved in the insulinotropic action of long-term DPP-IV inhibition (Flock et al. 2007). However, the magnitude of the effects of enhanced GLP-1 and GIP signaling by long-term DPP-IV inhibition on body weight and insulin secretion has not been determined.

In the present study, we investigated the long-term effects of DPP-IV inhibition on body composition and insulin secretion using high fat diet (HFD)-fed wild-type (WT) and GLP-1R knockout (GLP-1R−/−) mice.

Section snippets

Animals

Mice (C57BL/6 background) were housed under a light/dark cycle of 12 h with free access to food and water. As ingestion of a meal rich in fat is a strong stimulus of incretin signaling (Harada et al. 2008), male WT and GLP-1R−/− mice were fed a high fat diet (45% fat, 20% protein and 35% carbohydrate by energy) from 7 weeks of age. Groups of treated HFD-fed WT and GLP-1R−/− mice received DPP-IV inhibitor in drinking water (0.5% W/V), while groups of untreated HFD-fed WT and GLP-1R−/− mice

Body weight and body composition of DPP-IV inhibitor-treated HFD-fed mice

Water intake, food intake, and body weight of HFD-fed WT and GLP-1R−/− mice with or without DPP-IV inhibitor administration were measured. In WT mice, water and food intake in DPP-IV inhibitor-treated and untreated mice were similar during the 8 weeks of the study (Fig. 1A). In GLP-1R−/− mice, water and food intake in DPP-IV inhibitor-treated and untreated mice also were similar (Fig. 1A). A significant difference in body weight between DPP-IV inhibitor-untreated WT and GLP-1R−/− mice appeared

Discussion

In the present study, we evaluated body composition and glucose control in the absence of the GLP-1 signaling using GLP-1R−/− mice treated with DPP-IV inhibitor for 8 weeks to clarify GLP-1 and GIP action under long-term DPP-IV inhibition.

HFD-fed DPP-IV-deficient rodents exhibit reduced food intake and resistance to development of obesity with elevated active GLP-1 levels (Yasuda et al., 2002, Conarello et al., 2003), and DPP-IV inhibitor has been shown to reduce body weight in some previous

Conclusion

Long-term DPP-IV inhibition does not alter body composition, possibly due to the counteracting effects of enhanced GLP-1 and GIP, but does improve glucose tolerance through the synergistic insulinotropic effects of enhanced GLP-1 and GIP, as well as by improved glucose responsiveness in pancreatic islets.

Acknowledgments

We thank Dr. Daniel. J. Drucker (Department of Medicine, The Banting and Best Diabetes Centre, Toronto General Hospital, University of Toronto, Toronto, Canada) for providing the GLP-1R−/− mice.

The funding of this study was supported by Scientific Research Grants from the Ministry of Education, Culture, Sports, Science, and Technology (Japan) and from the Ministry of Health, Labor, and Welfare (Japan).

References (29)

  • FlockG. et al.

    Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of Vildagliptin in mice

    Diabetes

    (2007)
  • GreenB.D. et al.

    Function of a long-term, GLP-1-treated, insulin-secreting cell line is improved by preventing DPP IV-mediated degradation of GLP-1

    Diabetes, Obesity & Metabolism

    (2005)
  • HansotiaT. et al.

    Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure

    The Journal of Clinical Investigation

    (2007)
  • HaradaN. et al.

    A novel gastric inhibitory polypeptide (GIP) receptor splice variant influences GIP sensitivity of pancreatic {beta}-cells in obese mice

    American Journal of Physiology. Endocrinology and Metabolism

    (2008)
  • Cited by (11)

    • Nutritional characteristics and bioactive compound content of guava purees and their effect on biochemical markers of hyperglycemic and hypercholesterolemic rats

      2017, Journal of Functional Foods
      Citation Excerpt :

      DP-IV is a membrane-associated peptidase that is distributed in various tissues and inactivates the insulinotropic peptides, glucagon-like peptide 1 (GLP-1) and the glucose-dependent insulinotropic polypeptide (GIP). Both of these are considered potent insulin secretion stimulants; thus, the inhibition of DP-IV leads to enhanced the insulin secretion and sensitivity (Liu et al., 2009). In diabetic conditions, la DF or TIIF of fruit purees may stimulate the short-chain fatty acid production, which enhances the glucose oxidation, reduces the free fatty acid release and improves the insulin sensitivity.

    • The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice

      2014, European Journal of Pharmacology
      Citation Excerpt :

      DPP-4-deficient rodents exhibit resistance to high-fat diet-induced obesity (Conarello et al., 2003; Yasuda et al., 2002). Several DPP-4 inhibitors (including teneligliptin) have been shown to be resistant to body weight gain, whereas most DPP-4 inhibitors have been reported to be non-resistant (Kern et al., 2012; Kim et al., 2012; Lamont and Drucker, 2008; Liu et al., 2009). The currently available DPP-4 inhibitors have shown conflicting data with respect to body weight in high-fat diet-fed mice.

    • Combination of TS-021 with metformin improves hyperglycemia and synergistically increases pancreatic β-cell mass in a mouse model of type 2 diabetes

      2011, Life Sciences
      Citation Excerpt :

      This experimental model exhibits metabolic disorders including an impaired insulin secretory capacity of pancreatic β-cells, obesity, glucose intolerance, and hyperglycemia, resembling the characteristics seen in human T2DM, compared with other genetic models including db/db mice or ob/ob mice which develop hyperphagia caused by leptin deficiency associated with extremely high plasma insulin level, rarely seen in human subjects. TS-021 was previously shown to be a DPP-IV inhibitor that has a favorable pharmacokinetic-pharmacodynamic profile and improves glucose tolerance in association with increases in plasma active GLP-1 and insulin levels in Zucker fatty rats (Tajima et al., 2011) and diet-induced obese mice (Liu et al., 2009). Metformin is a first-line oral anti-diabetic agent with a documented glucose-lowering effect in both obese and non-obese subjects with T2DM, which has recently been reported to promote GLP-1 secretion from enteroendocrine cells in the gut (Migoya et al., 2010).

    View all citing articles on Scopus
    View full text